

Immune Modulation: Therapeutic Interventions

Sahar Swidan, Pharm.D., ABAAHP, FAARFM, FACA

Disclosures

- Employment: Pharmacy Solutions
- Speaker: A4M, Amgen, Biohaven



Partners

• Financial support was provided for this course through an educational grant from KBMO Diagnostics and Your Financial Pharmacist.



Objectives

- Discuss novel therapeutic approaches for modulating immune response
 - Review stressors that affect the immune system and toll like receptors.
 - Review the use of peptides in immune support.
 - Discuss the various uses of LDN in the treatment of autoimmune conditions.
 - Review the various botanicals to support immunocompetency.











Sahar Swidan, Pharm.D, FAAFM, FACA

A Properly Functioning Immune System Is...

Surveillance

Internal Regulation

Tolerant

Resolution

Restorative





Innate Immune Cells: Neutrophils

Neutrophils are the body's first line of cellular defense against foreign invaders and constitute the major cell type involved in acute and some forms of chronic in inflammation.

The most prevalent leukocytes in the bloodstream, typically constituting more than 50% of all bloodstream leukocytes.

Considered surveillance cells that sweep through the blood- stream, scanning for tissue infections or other inflammatory events. Unfortunately, the capacity of neutrophils to destroy foreign organisms is matched in some circumstances by a capacity for host tissue destruction.



Innate Immune Cells Macrophages

Macrophages (and their precursors, monocytes) are the 'big eaters' of the immune system. Reside in every tissue of the body, albeit in different guises — such as microglia, Kupffer cells and osteoclasts

Engulf apoptotic cells and pathogens and produce immune effector molecules. Various types of macrophages are found throughout the body, including the brain, such as microglial cells. Microglia account for 10–15% of all cells found within the brain.



- A type of pattern recognition receptor (PRR) are TLRs
- Human genome codes for 10 known TLRs
 - Each recognize specific microbial products
- Lipoproteins of *Borrelia burgdorferi* are recognized by heterodimers of TLR1 and TLR2
 - Leads to activation of downstream signaling pathways and the translocation of nuclear factor kappa B (NFkB)
 - Leads to release of cytokines and chemokines





- TLR1 and TLR2 may also affect *Borrelia burgdorferi* gene expression
- *Borrelia burgdorferi* TLR also plays a role in:
 - Phagocytosis
 - Antigen presentation
 - Development of the adaptive immune response
- TLR is important in the inflammatory response of *Borrelia burgdorferi*





If the innate immune system is unsuccessful in destroying the pathogens, after about four to seven days the specific adaptive immune system responds.

Adaptive defense takes longer, but targets the pathogen more accurately.

Another advantage: It can remember the aggressor and acts specifically against certain antigens since it contains memory cells





Heavy metals and the immune system



Intro to heavy metals⁴⁹

- Many metals are natural in the environment as organic or inorganic compounds
- Industrial and combustion processes release heavy metals into the air, which leads to deposition and contaminates the soil
- Heavy metals are mostly absorbed in the airways or via the intestines
- Through the respiratory tract, low concentrations of heavy metals can affect endothelial cells, epithelial cells, and alveolar macrophages





heavy metals 50

- Metals can have a primary or secondary effect on the immune system
- Some heavy metals may give rise to disordered function of the immune system
 - Result in increased susceptibility to infection, hypersensitivity reactions, autoimmune diseases, and neoplasia



Suppression of the immune system⁶¹

- Heavy metals suppress the immune system in times when the immune system needs to destroy cells
- This leads to the following:
 - Increased free-radical activity and oxidative processes
 - Premature aging and aging diseases
 - Suppression/Deregulation of the immune system
 - Increase in cancer mortality
 - Increase risk of heart disease



Sleep deprivation and the immune

- Chronic sleep deprivation affects your hormones
 - It can impair glucose tolerance and lead to diabetes and cardiovascular disease
 - Increases cortisol levels leading to a higher risk of diabetes and obesity
- During the night in the early stages of sleep, immune cells often peak in concentration
 - T helper cells
 - Antigen presenting cells
- Sleep deprivation leads to an increase in inflammation





Autoimmune Disease

There are varying symptoms depending on the disease

 Common symptoms include low grade fever, pain in joints, and fatigue These diseases result in a person's body attacking its own tissues

 In a normal immune system, the antibodies attack antigens





- Environmental triggers
- Infection
- Certain foods (Ex. Gluten)
- Chemical exposures
- Pharmaceutical drugs
- Extreme stress or physical FUNCTIONAL trauma









Fibromyalgia

A common neurological health condition that causes <u>widespread</u> pain and tenderness (sensitive to touch) Many people who have this are very fatigued and have sleep issues

Causes are unclear Diagnosis made based on symptoms



Pain Processing in Fibromyalgia

Brain activity in response to experimental pain is heightened in these patients

•Attributed to the increased pain sensitivity seen

Higher levels of substance P in CSF

•Substance P important for neuroprocessing, so it contributed to the abnormal pain processing Lower levels of serotonin are found in fibromyalgia patients

Serotonin important for descending pathway
Blocked pain transmission for the periphery
Blocked serotonin can contribute to the pain seen in fibromyalgia



Women and Autoimmune

- Females have greater basal and stimulated axis activity compare to men
- Females also have more pronounced immune/inflammatory reaction compared to that of men
- Women have a higher incidence of autoimmune disorders
- The overall higher occurrence in women may be attributed to the gonadal steroid regulation of the HPA axis and inflammatory mediators

Autoimmune Diseases sproportionately Affecting Womer





Systemic lupus erythematous (SLE)⁵⁷

- It is a chronic autoimmune disease
- Characterized by production of autoantibodies
- Affected by environmental, genetic, infectious, and hormonal factors
- This disease predominates in reproductive-aged women
- Females with this disease have an increase in testosterone oxidation, leading to decreased testosterone levels
 - Independent of the severity of the disease
 - Also decreases in DHEA

Most common symptoms of Systemic lupus erythematosus





Rheumatoid Arthritis⁵⁵

- Hypothalamic-pituitary-gonadal (HPG) axis function and adrenal androgen (AA) are interrelated
 - Play a role in rheumatoid arthritis
- In rheumatoid arthritis, the concentration of glucocorticoid receptors in circulating lymphocytes are reduced
 - Glucocorticoid resistance in target tissues
- Thought to be less likely in men due to the immunosuppressive effect of androgens







Hormones and the immune system





Diagnostic Assays: Salivary Cortisol Patterns Matter

Flattening of the cortisol curve
Most predictive of adrenal dysfunction
Most well studied
Hypocortisolism induces:



Diagnostic Assays: Salivary Cortisol Patterns Matter





Cortisol Immune Connection



Loss of negative feedback from cortisol results in a rise in Th1 dominance



A new view on hypocortisolism

Eva Fries, Judith Hesse, Juliane Hellhammer, Dirk H. Hellhammer*

Department for Psychobiology, University of Trier, Johanniterufer 15, 54290 Trier, Germany

Received 18 November 2004; received in revised form 6 April 2005; accepted 6 April 2005

KEYWORDS Hypocortisolism; Cortisol; Allostatic load index;

Summary Low cortisol levels have been observed in patients with different stress-related disorders such as chronic fatigue syndrome, fibromyalgia, and post-traumatic stress disorder. Data suggest that these disorders are characterized by a symptom triad of enhanced stress sensitivity, pain, and fatigue. This overview will

Raison and Miller (2003) assume that prolonged or repeated exposure to immune stimuli might predispose an individual to reduced glucocorticoid signaling as a means of freeing bodily defenses from inhibitory control in the face of an ongoing infectious threat. Thus, an enhanced release of



A new view on hypocortisolism

Eva Fries, Judith Hesse, Juliane Hellhammer, Dirk H. Hellhammer*

Department for Psychobiology, University of Trier, Johanniterufer 15, 54290 Trier, Germany

Received 18 November 2004; received in revised form 6 April 2005; accepted 6 April 2005

KEYWORDS Hypocortisolism; Cortisol; Allostatic load index;

Summary Low cortisol levels have been observed in patients with different stress-related disorders such as chronic fatigue syndrome, fibromyalgia, and post-traumatic stress disorder. Data suggest that these disorders are characterized by a symptom triad of enhanced stress sensitivity, pain, and fatigue. This overview will

may be beneficial for health and survival. Most strikingly, the demonstration of a low allostatic load index in hypocortisolemic subjects suggests that a down-regulation of the HPA axis in chronically stressed subjects protects those subjects against the harmful effects of a high allostatic load index.





Myint, A.M., & Kim, Y.K. (2003) : Cytokine-serotonin interaction through IDO: A neurodegeneration hypothesis of depression. Med Hypothesis 61: 519- 525

DNAL IE








- No hormone works in isolation for other hormones
 - They are all interconnected
- Many hormones have an effect on the immune system, diseases, and other hormones
- An imbalance in thyroid, adrenal hormones (testosterone, estrogen, and progesterone) can affect the immune system
- The chemical environment and nutrition also contribute to hormone imbalance

Hormonal Balance







Thyroid hormone and the immune system^{64, 71}

- Thyroid hormone stimulates the activity of NK cells
- TSH can be produced by leukocytes
 - TSH may act as a cytokine-like regulatory molecule within the immune system
- TSH elicits elevated antibody responses and has potentiating effects on leukocyte proliferation



Adrenal gland and the immune system⁶⁴

- As a result of stress and nutritional deficiencies, the body produces hormones that inhibit the production of prostaglandins
 - This interferes with immune response
- Adrenal hormones deplete
 thymus function
 - Thymus gland is responsible for training T cells



Copyright @ 2006 Nature Publishing Group Nature Reviews | Immunology



Estrogen & Progesterone and the immune system⁶⁴

- NK cell activity and IL-2 are compromised by estrogen dominance and they are promoted by progesterone
- Estrogen has been shown to decrease the size of the thymus
 - This causes a reduction of thymic hormone in the blood
 - This depresses the immune system
- Autoimmune disorders are often associated with estrogen dominance
 - Occur more in women compared to men





Estradiol (E2)⁶⁶

- E2 increases TNF-αin immune cells
- E2 decreases IL-10 and NO synthesis in immune cells
 - However, E2 increases NO synthase activity in endothelial cells
- The effects of E2 can vary based on the different cell targets





Progesterone⁶ 5

- High progesterone levels are immunosuppressive
 - May contribute to the beneficial effects of pregnancy on rheumatoid arthritis
- Progesterone suppresses immune responses
 - Been show to suppress cellmediated immunity
 - It enhances suppressor cell activity
 - It inhibits mitogen induced lymphocyte proliferation







anti-inflammatory effects

- Inhibits TNF-α and NO
- Induces synthesis of IL-10
- Testosterone can be mediated by its own nuclear receptor
- Androgens and estrogen operate in an opposite matter
 - They work to either suppress (E2) or activate (testosterone) cell function



Prolactin and Growth Hormone^{65, 72}

- Prolactin (PRL) and growth hormone (GH) are needed for the development of the immune system and the function of immunostimulators
- Prolactin restores the immune response
- Those who are deficient in growth hormone have thymic atrophy and are immunodeficient
 - Growth hormone receptor are present on lymphocytes







CRH and Vasopressin on immunity⁷²

- There is an increase in the secretion by the pituitary and adrenal glands following inflammation
- IL-1, IL-6,, and TNFαdirectly stimulate the synthesis and secretion of CRH and vasopressin at the hypothalamus
- This activation of the pituitary-adrenal axis leads to a lower intensity of the immune response because all of the components of the immune response are inhibited by cortisol



DHEA⁶⁶

- A decline in the body's DHEA levels cause a decline in immune function
- DHEA impact T cell function
 - DHEA regulates IGF-1
 - IGF-1 regulates T lymphocyte function – including TH1 to TH2 balance via IL-12 production





DHEA⁶⁸

- DHEA stimulates production of IL-2
- It inhibits NK cells differentiation
- DHEA prevents increase in agerelated IL-6 production in lymphocytes







Immunoregulatory Peptides

Background

- Peptides on "fringes" of medicine until recently
- Past Problems
 - High costs
 - Limited availability
 - Short half-lives
 - Lack of oral bioavailability
 - Side effects
 - Poor patient compliance with injections
 - Regulatory environment
 - Sub-quality products readily available on internet





Background • What Changed?

- •Genomics, Metabolomics, Proteomics
- Recombinant technology and genetic engineering
- Pharma directed
- Improved bioavailability
- Decreased side effects
- Improved efficacy and safety



Immune Peptides





Thymosin Alpha 1

- Synthetic thymic peptide
- 28 amino acids
- MW = 3108.28
- Modulates innate immunity
- Pleiotropic immune modulation
- Helps maintain Immune homeostasis
- Toll-like receptor (TLR)9 agonist
- Vaccine agonist





Thymosin Alpha 1

- Promotes T cell differentiation and maturation
 - In vivo and in vitro data
- Decreases T cell apoptosis
- Improves Th1 responses
- Balances Th1/Th2
- Activates indoleamine 2.3-dioxygenase enzyme

Yang X, Qian F, He H, et al. Effect of thymosin alpha-1 on subpopulations of Th1, Th2, Th17 and regulatory T cells (Tregs) in vitrol. Braz J Med Biol Res. 2012;45(1):25-32.

Romani L, MorettiS, Fallarino F, et al. Jack of all trades: thymosin alpha-1 and its pleiotropy. Ann NY Acad Sci. 2012;1269:1-6.

Thymosin Alpha 1

- Promotes IFN type 1 production
- Decreases immune senescence
- Activates CD3+, CD4+, CD8+
- Improves production of IL-1 beta, IFN-γ, IL-2, IL-3,
- IL-6, IL-10
- Improves NK cell activity and TNF-alpha
- Inhibits viral replication
- Antioxidant

Yang X, Qian F, He H, et al. Effect of thymosin alpha-1 on subpopulations of Th1, Th2, Th17 and regulatory T cells (Tregs) in vitrol. Braz J Med Biol Res. 2012;45(1):25-32.

Romani L, MorettiS, Fallarino F, et al. Jack of all trades: thymosin alpha-1 and its pleiotropy. Ann NY Acad Sci. 2012;1269:1-6.

Th1 Th2 Imbalance

Studies report immune dysfunction is associated with a • Chronic wide-variety of common chronic illnesses

- Chronic Stress
- Depression
- Metabolic Syndrome
- Weight management issues
- Insulin resistance and type 2 diabetes
- Anti-Aging effects increased Food allergies or sensitivities oxidative stress
- Chronic fatigue syndrome/fibromyalgia
- Autoimmune conditions

- Cancer
- Environmental toxins
- Chronic infections, including Lyme, viruses, candida and many parasites
- Glutathione depletion consistently results in TH1-TH2 shift
- Dysbiosis
- Zinc and selenium deficiencies





Ta1 Applications

- Conditions requiring immune response modulation
- COVID-19 immune support restoration of lymphocytopenia
- Hepatitis B and C
- Treatment of HIV/AIDS
 - Can be used in conjunction with oral antiretroviral treatments
- Cancer treatment/chemotherapy adjunct
 - Non-small cell lung , hepatocellular, malignant melanoma
- DiGeorge's Syndrome

Rasi G, Terzoli E, Izzo F, et al. Combined treatment with thymosin alpha 1 and low-dose interferon alpha after dacarbazine in advanced melanoma. Melanoma Res. 2000;10:189-192.



Ta1 Dosage

- •3mg/ml 5ml vial
- •450mcg (0.15ml) SQ 1-2 x daily OR 1.5 mg (0.5 ml) SQ every 3rd day
- Treatment from 2 weeks for viral infection and 3 months or longer for HIV/ cancer / Hepatitis B, C or complicated immune suppression or over-activation
- Multiple overlap of usage
- •Transient increases in ALT have been reported to occur
- Do not use in individuals being deliberately immunosuppressed.

Yang X,, et al. Effect of thymosin alpha-1 on subpopulations of Th1, Th2, Th17 and regulatory T cells (Tregs) in vitrol. Braz J Med Biol Res. 2012;45(1):25-32.



Safety - Zadaxin®

- Chinese patented thymosin alpha-1
- Approved in over 35 Countries
- Well tolerated
- Used in over 300,000 patients
- No significant side-effects
- Used in elderly up to 101 yrs and children 13 months
- No SE's like interferon
- None of these studies led to an irreversible or overtly inflammatory immune system response when using Ta1



Thymosin Beta-4

- TB4 or TB-500
 - Originally isolated from calf thymus
 - \circ More ubiquitous occurs in most all cells
 - \circ 43 amino acids
 - Ac-Ser-Asp-Lys-Pro-Asp-Met-Ala-Glu-Ile-Glu-Lys-Phe-Asp-Lys-Ser-Lys-Leu-Lys-Lys-Thr-Glu-Thr-Gln-Glu-Lys-Asn-Pro-Leu-Pro-Ser-Lys-Glu-Thr-Ile-Glu-Gln-Glu-Lys-Gln-Ala-Gly-Glu-Ser
 - \circ Higher levels in platelets and white cells





TB4

- Helps decrease scar tissue formation
 - Reduces level of myofibroblasts

- Also supports immunity
 - Antimicrobial
 - Improves T cells
 - Use with Thymosin alpha 1

• Neuroprotective

Reti R, Kwon E, Qui P, et al. Thymosin B4 is cytoprotective in human gingival fibroblasts. Eur J Oral Sci. 2008;116(5):424-30.

Popoli PR, Pepponi A, Martire et al. Neuroprotective Effects of Thymosin B4 in Experimental Models of Excitotoxicity. Ann. N.Y. Acad. Sci.2007;1112: 219–224.





Reti R, Kwon E, Qui P, et al. Thymosin B4 is cytoprotective in human gingival fibroblasts. Eur J Oral Sci. 2008;116(5):424-30. Popoli PR, Pepponi A, Martire et al. Neuroprotective Effects of Thymosin B4 in Experimental Models of Excitotoxicity. Ann. N.Y. Acad. Sci.2007;1112: 219–224.

- Soft Tissue Repair tendon, ligament, muscle
 - Sports/athletic injuries
- Pressure or venous stasis ulcers
- Conditions requiring immune response modulation
- Brain issues if autoimmunity suspected
- Ischemic stroke

Kleinman HK, Sosne G. Thymosin B4 promotes dermal healing. Vitam Horm. 2016;102:251-75.



- Spinal cord injuries
- TBI / concussion (in conjunction with BPC-157)
- Dry eye disorders
 - Phase II clinical trials RegeneRx
- Corneal injuries
- Phase 3 US trial for Epidermolysis bullosa
- Lung inflammation fibrosis
- May improve hair growth



- Cardio protection
 - Improves cardiac wound repair
 - Antifibrotic
 - Proangiogenic
 - Reduces infarct volume and preserves cardiac function in preclinical

Continuing Educatio

models of cardiac ischemic injury.

- Used in hypoxic heart disease
- NAFLD (non alcoholic fatty liver disease)
 - Inhibits oxidative stress
 - Decreases proinflammatory factors
 - Decrease hepatic fibrosis

Shrivastava S, Srivastava D, Olson EN, et al. Thymosin beta4 and cardiac repair. Ann NY Acad Sci. 2010;1194:87-96. Jiang Y, Han T, Zhang Z, et al. Potential role of thymosin beta 4 in the treatment of nonalcoholic fatty liver disease. Chron Dis Trans Med. 2017;3:165-68.

- Decreases endotoxemia use in sepsis and elevated LPS
- Reported in lab studies to reduce polymerization
 for G-actin into F-actin
- Improves mortality rate

Badamchian M, et al. Thymosin beta 4 reduces lethality and down-regulates inflammatory mediators in endotoxin-induced septic shock. Int Immunopharmacol. 2003;3(8):1225-33.



TB4 Dosage

- General dosage
 - 300 mcg 1 gram daily, SubQ
 - Depending upon clinical presentation
 - Do not dose for more than 3 months
 - Cycle if needed long-term 3 months on, 1 month off
- TB4 use with Thymosin alpha 1 and BPC-157 concurrently
- Individual dosage requirements may vary based on clinical presentation



- Body protection compound 157
- Pentadecapeptide MW 1419
- Gly-Glu-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val
- Focuses on Gut-Brain Axis
- Human BPC is found in gastric juices





Sikiric P, et al. Brain-gut axis and pentadecapeptide BPC 157: Theoretical and Practical Implications. Curr Reuropharmacol. 2016;14(8):957-865.



- Gastric protection
 - Antiulcer peptidergic agent
 - Cytoprotective
 - Nitric Oxide (NO) improvement



- BPC 157 interacts with nitric oxide (NO)

system, both NOS-substrate (L-arginine) and NOSblocker (L-NAME), including the regulation of a blood pressure

- Helps improve GI mucosal integrity
- Ulcerative colitis in lab studies
- Decreases NSAID and alcohol gastric side effects



- Helps heal tissues
 - Reported to improve cell survival under oxidative stress
 - Increased fibroblast migration and dispersal
 - Induces F-actin formation in fibroblasts
 - Improves angiogenesis
 - Enhances vascular expression of VEGFR2
 - BPC-157 increases the extent of phosphorylation of paxillin and FAK proteins without affecting the amounts produced
- used in deep skin burns, corneal injuries
- injured muscle, tendon, ligament or bone



- Neuroprotective
 - Influences serotonergic, dopaminergic, opioid and GABAergic systems
 - Improves nerve regeneration
 - Decreases neuroinflammation
 - May help in depression
 - Ameliorates alcohol withdrawal symptoms and opposes alcohol intoxication


BPC 157

- Cardioprotective
 - May help regulate blood pressure
 - Nitric oxide improvement
 - BPC 157 rapidly and permanently counteracts the QTc prolongation induced by neuroleptics (such as haloperidol, fluphenazine, clozapine, olanzapine, quetiapine) and prokinetics

Strinic D, et al. BPC 157 counteracts QTc prolongatino induced by haloperidol, fluphenazine, clozapine, olanzapine, quetiapine, sulpiride and metoclopramide in rats. Life Sciences. 2017;186(1):66-79.



Seiwerth S, et al. BPC157 and blood vessels. Curr Pharm Des, 2014;20(7):1121-35.

BPC 157 -Dosage

- SubQ
 - Half life approx. 4 hours
 - 400 600 mcg/day total
 - If injury specific = split dosing into 20-300 mcg BID
 - Oral = 500 mcg daily
- Corticosteroids may reduce BPC-157's ability to heal muscles
- Results can be spontaneous and improve over 2-4 weeks treatment
- Safe in recommended dosages

Pevec D, et al. Impact of pentadecapeptide BPC 157 on muscle healing impaired by systemic corticosteroid application. Med Sci Monit. 2010;16(3):BR81-88.



LL-37



- LL-37 is a cathelicidin antimicrobial peptide
- Part of a mammal's innate immunity natural antibioτις
- Endogenously expressed in epithelial cells of the testis, skin, the gastrointestinal tract, and the respiratory tract, and in leukocytes such as monocytes, neutrophils, T cells, NK cells, and B cells
- Disrupts microbe's outer membrane
- Also exerts "alarmin" activity recruits immune and inflammatory cells
- Possibility for use in COVID-19 infections
- Dose
 - 2,000 mcg/ml 5ml vial
 - General dosage: 0.1 ml (200 mcg) SQ daily for 6-8 weeks
 - Add vitamin D3 5,000 IU (125mcg) daily if level < 50ng/ml
 - LL-37 is activated in the body by vitamin D

Low-Dose Naltrexone Studies



Low Dose Naltrexone (LDN)

- Dose: 3 to 4.5 mg/d
 - Hypothesized to increase production of endogenous opioids during short term blockade of opioid receptors
 - Involved in growth and in the immune system and immune modulation

Effects of Opioids on the Immune System



Schematic representation of the hematopoietic system showing the differentiation pathways sensitive to opioids. *from Effects of Opioids on the Immune System – Roy S. and Loh H.H., Neurochemical Research, 21:1375-1386, 1996*





MECHANISM OF ACTION OF LDN



The Use of LDN as a Novel Anti-Inflammatory Treatment for Chronic Pain

- Review of evidence that LDN may operate as a novel anti-inflammatory agent in the central nervous system, via action of microglial cells
- Currently used in fibromyalgia, Crohn's disease, multiple sclerosis, and complex regional pain syndrome
- Effects may be unique to LDN and appears to be independent from naltrexone's better known activity on opioid receptors
- LDN is well tolerated
- Current literature has small sample sizes, and few replications have been performed to help promote data
- LDN may represent on of the first <u>glial cell</u> <u>modulators</u> to be used for the management of chronic pain disorders

Initial Findings of an **Open-Label** Trial of Low-Dose Naltrexone for Symptomatic Mesenteric Panniculitis

- Lack of prospective studies and appropriate treatments for mesenteric panniculitis
- 4.5 mg for 12 weeks administered to 3 patients
- <u>Primary endpoint</u>: reduction in Mesenteric Panniculitis Subjective Assessment Score
- ESR and c-reactive protein tested at baseline
- All 3 patients had decrease in MPSAS at 4 weeks
 - 2 of 3 had decrease at 8 weeks
- <u>Conclusion</u>: LDN was safe, had minimal side effects, and showed efficacy in patients with symptomatic mesenteric panniculitis
- Further studies need to be conducted

Low Dose Naltrexone for Treatment of Multiple Sclerosis

- Retrospective chart review of safety and tolerability
- Multiple sclerosis is autoimmune disease of central nervous system
- Chart review of 215 patients with MS given oral LDN
- Study showed significant number of combination therapy of immunomodulating agent and LDN
- LDN did not cause any unexpected side effects and did not potentiate side effects of immunomodulating therapies

Low Dose Naltrexone Treatment of Established **Relapsing-**Remitting Experimental Autoimmune Encephalomy elitis

- Examined the modulation of opioid growth factor with low doses of naltrexone as disease modifying therapy for relapse-remitting autoimmune encephalomyelitis
- LDN treatment reduced behavioral scores across the 40 day observation point
- LDN increase the length of remission as well as the duration of mild disease
- Conducted in mice, so needs to be demonstrated in humans as well in further studies

Off-Label, LDN for Refractory Painful Diabetic Neuropathy

- 2 mg dose of LDN showed to have partial improvement in burning pain of diabetic neuropathy
- 4 mg dose for 2 weeks produced even better pain relief
- Sleep improved after the treatment
- On examination, there was no hyperalgesia, but the sensory loss was not improved
- Initially, mild diarrhea, nausea, and somnolence occurred with treatment but subsided spontaneously after a few days
- Proposed mechanisms includes:
 - Opioid receptor blockage causing compensatory release of endogenous opioids
 - Antagonism of TLR-4 on microalga, which produces a variety of inflammatory factors such as pro-inflammatory cytokines, substance P, nitric oxide, and excitatory amino acids

Low-Dose Naltrexone for the Treatment of Sarcoidosis

- Case report of a patient with Systemic sarcoidosis treated with LDN
- LDN increased endorphin levels and helped regulate inflammation including lymphocyte activity
- Radiographic improvement was seen
- Clinical improvement marked by less fatigue and no more need for antibiotic therapy for a sarcoid rash
- Unclear is the perceived improvement in dyspnea is directly responsible from the LDN
- Fatigue is the most common problem in sarcoidosis and can be secondary to pulmonary hypertension, chronic inflammation, infections, and drug side effects
 - LDN may have improved fatigue by reducing inflammation burden

Low-Dose Naltrexone Treatment of Familial Benign Pemphigus

- 3 patients with biopsy proven recalcitrant Hailey Hailey Disease were evaluated and treated with LDN 1.5 mg to 3 mg
- Clinical response included healing of erosions, improvement of erythema, and alleviation of pain
- 3 patients exhibited at least 80% improvement in extent of disease
 - One patient had 90% clearance
 - All 3 patients had substantial improvement in QOL
- No adverse effects recorded

Naltrexone Inhibits IL-6 and TNFalpha

- Analyzed effects of LDN on IL-6 secretion by peripheral blood mononuclear cells
 - In vitro following stimulation with ligands for TLR4 and for intracellular receptors TLR7, TLR8, and TLR9
- Naltrexone did not affect cell viability or induce apoptosis of PBMC
- Intracellular staining showed that naltrexone inhibited production of IL-6 and TNF-alpha by monocyte and plasmacytoid dendritic cell subsets
 - Within PBMC population following treatment with ligands for TLR7/8 and TL9, respectively

Naltrexone Inhibits IL-6 and TNFalpha

- Naltrexone inhibited IL-6 production in isolated monocytes and B cells after TLR7/8 and TLR9 stimulation
- Findings indicate that naltrexone has potential to modulate the secretion of inflammatory cytokines in response to intracellular TLR activity
 - May have potential for use as an immunomodulator

LDN for Breakthrough MDD on Antidepressants

- Dopaminergic mechanisms of LDN proposed as augmentation for depressive breakthrough on prodopaminergic antidepressant regimens
- 12 adults with recurrent DSM-IV MDD on dopaminergic antidepressant regimens
 - Stimulants
 - Dopamine agonists
 - Bupropion \geq 300 mg/day
 - Aripiprazole < 2.5 mg/day
 - Sertraline \geq 150 mg/day
- Given LDN 1 mg BID or placebo for 3 weeks

LDN for Breakthrough MDD on Antidepressants

- All 12 subjects completed the trial
- Hamilton depression rating scale (HAM-D-17 scores decreased from 12.2 to 11.7 for LDN
- <u>Conclussion</u>: LDN augmentations showed some benefit for MDD relapse on dopaminergic agents
- Larger studies needed to confirm data

Reduced Pro-Inflammatory Cytokines after Eight Weeks of LDN for Fibromyalgia

- Fibromyalgia is a complex, multisymptom condition that predominantly affects women
- 10 week single-blind crossover trial to test the immune effects of eight weeks of oral administration of LDN
- 8 women enrolled
 - Average symptom severity was62 out of 100
 - Average symptom duration of 14 years

Reduced Pro-Inflammatory Cytokines after Eight Weeks of LDN for Fibromyalgia

- Found that LDN was associated with reduced plasma concentrations of interleukins
 - Including: IL-1beta, IL1Ra, IL-2, IL-4,
 IL-5, IL6, IL-10, IL-12p40, IL-15, IL 17A, IL-27, INF alpha, TGF-alpha
- 15% reduction of fibromyalgiaassociated pain and 18% reduction in overall symptoms
- Conclusion: LDN treatment in fibromyalgia is associated with a reduction of several key proinflammatory cytokines and symptoms
- More research needs to be conducted

Treatment of Hailey-Hailey Disease with Low-Dose Naltrexone

- Hailey-Hailey disease is a severe genetic blistering disease of intertriginous skin locations that can lead to poor QOL and increased morbidities
- The objective of this study was to determine if LDN is an effective treatment for Hailey-Hailey Disease
- Study was a case series performed at an outpatient dermatology clinic to 3 patients with severe Hailey-Hailey Disease recalcitrant to at least 4 therapies
- LDN 3 mg nightly, titrated to 4.5 mg in 2 patients
- Reductions in the size of lesions as well as subjective improvement of symptoms was found

Treatment of Hailey-Hailey Disease with Low-Dose Naltrexone

- All 3 patients noted significant healing of erosions and plaques starting from the peripheral aspect within 1 to 2 weeks of treatment
- Clinical resolution of lesions within 2 months of treatment
- Discontinuation of LDN resulted in flaring of symptoms, which cleared 2 to 3 days when rechallenged with LDN
- <u>Conclusion</u>: LDN is a novel therapy for Hailey-Hailey disease
- Possible mechanism may involve LDN influencing opioid or TLR signaling to improve calcium mobilization and improve keratinocyte differentiation and wound healing
- Further studies need to be conducted with larger samples sizes and to clarify the mechanism

CAM in Autoimmune Disease

Complementary Medicines have function in the modulation and relief of symptoms associated with autoimmune diseases. These supplements all work differently and influence different components of the immune system:

- Adaptive immune system
- Innate immune system
- Histamine/allergic immune system



CAM that Affect Innate Immunity

Astaxanthin	Curcumin	Gymnema	Vitamin A
Betaine HCI with pepsin	DHEA	L- Glutamine	Vitamin C
Carnitine	Ginger	Pycnogenol	Vitamin D
Cayenne pepper	Green Tea Extract	Resveratrol	Vitamin E
Coenzyme Q10	Glutathione	SAMe	5HTP



CAM that Affect Adaptive Immunity

Boswellia	Green tea extract	SAMe
Carnitine	Glutathione	Selenium
Cromolyn	Peony	Vitamin B6
Curcumin	Resveratrol	Vitamin D



CAM that Affect Histamine/Allergic Immunity

Borage Oil Evening primrose Ketotifen Selenium

Capsaicin	Curcumin	Omega-3	Vitamin C
Cat's claw	Ginger	Probiotic	Vitamin E
Coenzyme Q10	Green tea extract	Rosemary	White willow bark







Specialized Pro-Resolving Lipid Mediators

- Biosynthesized in the resolution phase of acute inflammation and the mediators are potent agonists that control the duration and magnitude of inflammation.
- Four distinct new chemical families: lipoxins, resolvins, protectins and maresins, which are involved in acute inflammation.
- Resolvins and protectins are derived from ω3-unsaturated fatty acid-derivatives
- For example, Resolvin E1 binds G coupledprotein receptors on monocytes, macrophages and dendritic cells to attenuate TNF-mediated NFkB activation

Pro-Resolving Mediators Characteristics

Stop of inflammatory cell recruitment

Induction of neutrophil apoptosis and clearance

Egress of immune cells

Positive modulation of the immune response

Induction of tissue repair









- Non-essential amino acid fundamental to the digestive and immune systems
 - Essential for lymphocyte function
- Helps repair damage to the gut
 - Helps the gut lining to regrow and repair
- Increases number of cells in the small intestine along with the number and height of villi of those cells



- Type 1 Diabetes Mellitus
- Crohn's Disease
 - Increase permeability of intestinal wall
 - Improve the ability for vital substances to properly come through the body





Proteolytic Enzymes

- Common proteolytic enzymes: pepsin, bromelain, papain
- Mechanism of Action
 - Digest protein by aiding in the digestion process, breaking it down into amino acids
- Safety
 - Generally safe







Betaine Hydrochlori de with Pepsin





Betaine Hydrochloride with Pepsin

Multiple Sclerosis

3.9 mg/kcal
37x what is found in the human diet

Hashimoto's Thyroiditis

- Low stomach acid makes it more difficult to digest
- People with Hashimoto's can be sensitive to gluten, dairy, and soy
- Because the proteins are difficult to digest
- Betaine with pepsin can help with better digestion


Omega-3 Fatty Acids

- Help reduce inflammation
- Highly concentrated in the brain and important for cognition
- **Side effects:** flatulence, bloating, belching, diarrhea





Omega-3 Fatty Acids: Uses

Rheumatoid Arthritis	Systemic Lupus Erythematosus	Inflammatory Bowel Disease
Fish oils helps reduce symptoms of RA, including joint pain and morning stiffness One study suggest that people with RA who take fish oil may be able to lower their dose of NSAIDs Does not slow progression of RA, only treats symptoms	EPA and fish oil may reduce symptoms of SLE Two studies found that fish oil had no effect on lupus nephritis	Mixed results Some studies suggest that omega-3 fatty acids may help when added to sulfasalazine More studies needed Have similar side effects to IBD: flatulence, belching, bloating, diarrhea



Borage Oil (*Borago* officinalis): Uses

Rheumatoid Arthritis

- Take in combination with conventional treatment
- Decrease symptoms of RA after 6 weeks of treatment
- Improvement sustained for 24 weeks
- Can decrease number of tender joints by 36%, swollen joints by 28%
- Dose: 1300 mg of oil daily





Evening primrose (*Onangracea* e)

- A wildflower
- Has 7 -10% GLA
 - Same fatty acid in borage oil
- <u>Side effects</u>: nausea, diarrhea, rashes
- Do not take if have epilepsy
- Rheumatoid Arthritis
 - Arthritis Research UK validated the effectiveness of evening primrose for RA
 - Helps the immune system and joint function
 - Dosage: 540 mg of the oil twice daily
 - May take 6 months for clinical efficacy



Vitamin D3

- Mechanism of Action
 - Immunologic effect
 - May inhibit autoimmune reactions that target cells in the body
 - Modulates the activity of immune cells





Vitamin D3

- Plaque Psoriasis
 - Used topically
 - Can be used in combination with corticosteroids such as betamethasone
- Multiple Sclerosis
 - Decreases risk of MS in women by up to 40% (dose-dependent, 400 IU daily)
- Rheumatoid Arthritis
 - Increased vitamin D intake associated with lower risk of RA
- Systemic Lupus Erythematosus
 - Lower vitamin D levels are linked to more aggressive lupus autoimmunity
 - Supplement with vitamin D to lessen symptoms
- Diabetes Mellitus Type 1
 - Helps prevent incidence and associated complications

vitamin

Cholecalciforol

Vitamin

Coenzyme Q-10

- Biosynthesis of CoQ-10 is a 17-step process requiring riboflavin, niacin, pantothenic acid, pyridoxine, b12, folic acid, vitamin C, and other trace elements
- Generates ATP
- Has antioxidant effects
- Has anti-inflammatory effects by attenuating TNF-alpha on peroxisome proliferator-activated receptor gamma (not alpha)
- Immunomodulatory agent
 - Needed for optimal function of the immune system







Diabetes Mellitus Type 1 • Q-10 200 mg BID may reduce A1C



Fibromyalgia • Q-10 200 mg daily for 84 days improves QOL such as physical fitness levels, social activities, overall health, and pain



DHEA

- Decreases with age
- Linked to a variety of chronic and degenerative diseases
- As a result of aging, immunity may become compromised due to poor regulation of cellular hormones that govern immune responses
- Has antioxidant effects
- Stimulatory effect on the immune system
- DHEA upregulates various parameters involved in the inflammatory pathway





DHEA

- Systemic Lupus Erythematosus
 - Adjunct treatment
 - Help improve SLE disease activity, frequency of flareups, muscle aches, oral ulcers, QOL and corticosteroid doses needed
 - More evidence needs to be conducted
- Inflammatory Bowel Disease
 - DHEA 200 mg/day orally for 8
 weeks reduced symptoms
 - Remission occurred in 6 of 7 Crohn's patients and 6 of 13 UC patients





Acetyl-Glutathione



- Antioxidant that is naturally produced in the body
- Mechanism:
 - During chronic inflammation during a period of sustained production of reactive oxygen species, antioxidant defense systems weaken
 - Glutathione stimulates and inhibits immunological response to control inflammation
 - Plays a role in detoxification
 - Deficiency impairs the body's ability to get rid of toxins, so glutathione helps to prevent this





Curcumin

- Also known as turmeric
- Mechanism:
 - Anti-inflammatory effects
 - Antioxidant effects
 - Immunomodulator y effects





Curcumin







Curcumin



- Multiple Sclerosis
- Type 1 Diabetes Mellitus
- Rheumatoid Arthritis
 - May reduce symptoms including morning stiffness, walking time, and joint swelling compared to baseline
 - Curcumin 500 mg BID reduced RA symptoms more than diclofenac sodium 50 mg BID after 8 weeks
- Systemic lupus erythematosus
 - Turmeric 1.5 g/day in 3 divided doses for 3 months can reduce systolic BP and improve kidney function compared to baseline in patients with lupus nephritis
- Inflammatory Bowel Disease
 - Curcumin 1.1 g/day orally for one month followed by 1.65 g/day for another month reduced symptoms of ulcerative colitis in patients taking 5-ASA and corticosteroids compared to baseline
 - Study showed that taking 2 g/d orally with sulfasalazine or mesalamine for 6 months can reduce the risk of ulcerative colitis recurrence compared to placebo



Boswellia

- The applicable part of boswellia is the gum resin
- Gum resin is obtained by pulling away the bark of the boswellia tree
- Gum resin contains up to 16% essential oils including
 - Phenyl propanoids, terpenoids, flavonoids, and other phenolics
- Has immunomodulatory effects and may inhibit mediators of autoimmune disorders
 - Reduce production of antibodies and cell-mediated immunity



5 – Loxin (Boswellia Serratia Extract)

- Mechanism of Action
 - Inhibit 5-lipoxygenase and reduces leukotriene synthesis
 - Inhibits leukocyte elastase
- Dose
 - 100-250mg daily by mouth
- Safety
 - Often used to treat pain and inflammation usually associated with arthritis
 - Well-tolerated orally





Boswellia servata.

Replached for the Authon Jon I. 1800

- Side Effects
 - Diarrhea
 - Nausea
 - Abdominal pain
 - Heartburn
 - Itching
 - Headache
 - Edema

C.Reid. det.

General Weakness

- Drug Interactions: dose adjustment might need to be made
 - CYPIA2 substrates
 - CYP2CI9 substrates
 - CYP2C9 substrates
 - CYP2D6 substrates
 - CYP3A4 substrates
 - Immunosuppresants

Weddellow

Boswellia: Uses USES AND BENEFITS

Inflammatory Bowel Disease

- Improve symptoms in ulcerative colitis
- Boswellia gum resin 350 mg TID significantly improved symptoms and disease markers of UC
- 82% of subjects achieved remission compared to 75% taking sulfasalazine
- Another study boswellial gum resin 300 mg TID improved symptoms and measures of disease pathology in about 90% of patients
 - 70% achieved remission as compared to 40% in the sulfasalazine group
- Boswellia extract 1200 mg TID for 6 weeks may reduce symptoms of Crohn's disease



S-adenosylmethionine (SAMe)

- Distributed throughout virtually all body tissues and fluids.
- Concentrations are highest in childhood and decrease with age.
- Plays an essential role in 100s of biochemical reactions
 - Transmethylation
 - Transsulfuration
 - Aminopropylation
- SAMe contributes to the synthesis, activation and/or metabolism of hormones, neurotransmitters, nucleic acids, proteins, phospholipids, and some drugs



Selenium

- Organic molecule
- In broccoli, garlic, and other selenium-accumulating plants
- Essential for activity of selenoproteins such as glutathione peroxidase enzyme
- Anti-inflammatory effects by inhibiting ROS and activation of feedback mechanisms
- Antioxidant effects
- Immune system effects
 - Selenium needed for proper functioning of neutrophils, macrophages, NK cells, T lymphocytes, and other immune mechanisms



Selenium: Uses

Hashimoto's Thyroiditis

- •using selenium reduced need for oral prednisone for symptom control in UC patients
- More evidence is needed to rate selenium for this Selenium 200 mcg daily in combination with levothyroxine reduced thyroid peroxidase by about 6-30% more than placebo after 3-12 months of treatment
- •Selenium improves measures of QOL, well-being and mood

Rheumatoid Arthritis

Selenium seen to improve QOL measures
Selenium 200 mcg/day improved joint swelling, tenderness, and morning stiffness
Also reduced need for supplemental cortisone and NSAIDs for symptom control

Inflammatory Bowel Disease

•Combination supplement include



Resolution of Inflammation

Under normal conditions, neutrophils undergo apoptosis after performing their action at the inflamed site and macrophages ingest apoptotic neutrophils.

Clearance of apoptotic neutrophils prompts a switch from a pro- to an antiinflammatory macrophage phenotype (M1 to M2), is a prerequisite for macrophage egress via the lymphatic vessels favoring return to tissue homeostasis.

An active phenomenon, aimed at actively suppressing and extinguishing a vibrant inflammatory reaction



Inflammation: The Clinician's Challenge



General inflammatory Innate activation Auto-immune



What part of the immune is the generator?



What is the original cause?

And is it still around?

How do I resolve the inflammation?

ð

What about dysregulation of gene response?



SUMMARY

Key Takeaways

- Hormones play a role in modulating the immune system, so balance of hormones is a critical component of immunocompetency
- Low Dose Naltrexone have many therapeutic uses in immune system modulation.
- Nutriceuticals can be added for modulation if patient is unable to eat a healthier diet
- Peptide therapies is an emerging field of medicine



Questions?

- 1. Immune System 101. Aids.gov. . https://www.aids.gov/hiv-aids-basics/justdiagnosed-with-hiv-aids/hiv-in-your-body/immune-system-101/ (accessed April 20, 2015).
- 2. Hall JE. The microcirculation and lymphatic system. In: Hall JE, ed. *Guyton and Hall Textbook of Medical Physiology*. 12th ed. Philadelphia, PA. Elsevier Saunders; 2011: chap 16.
- 3. Concept 2: the two arms of the immune system. Immunopedia.org. http://www.immunopaedia.org.za/index.php?id=446 (accessed April 21, 2015).
- 4. Organs of the immune system. Texas A&M University. http://www.bio.tamu.edu/courses/microbio/notes/Organs%20of%20the%20Immune %20System.pdf. (accessed April 22, 2015).
- 5. The immune system and primary immunodeficiency. Immune Deficiency Foundation. http://primaryimmune.org/about-primary-immunodeficiencies/relevant-info/the-immune-system/. (accessed April 22, 2015).
- 6. Jones D, Min, W. An overview of lymphatic vessels and their emerging role in cardiovascular disease. *JCDR*. 2(3): 143-152.
- 7. What are lymphatic vessels? WiseGEEK. http://www.wisegeek.org/what-are-lymphatic-vessels.htm. (accessed April 22, 2015)



- 8. What is the thymus gland? WiseGEEK. http://www.wisegeek.org/what-is-the-thymus-gland.htm. (accessed April 23, 2015).
- Tonsils and adenoids. Hardin Memorial Health. http://www.hmh.net/HMHWebsite/Service.aspx?PageID=178. (accessed April 23, 2015).
- 10. A bacterial safe house: a new role for the appendix. Dartmouth Undergraduate Journal of Science. http://dujs.dartmouth.edu/winter-2008/a-bacterial-safe-house-a-new-role-for-the-appendix#.VTwV663BzGc. (accessed April 25, 2015).
- 11. Spleen: information, surgery, and functions. Children's Hospital of Pittsburgh of UPMC. http://www.chp.edu/CHP/organs+spleen+functions, (accessed April 25, 2015)
- 12. The gastrointestinal immune system. Colorado State. http://arbl.cvmbs.colostate.edu/hbooks/pathphys/digestion/basics/gi_immune.html . (accessed April 25, 2015).
- 13. How our immune system works. How Stuff Works. http://health.howstuffworks.com/human-body/systems/immune/immunesystem6.htm. (accessed April 26, 2015).
- 14. Immune cells. National Institute of Allergy and Infectious Diseases. http://www.niaid.nih.gov/topics/immunesystem/Pages/immuneCells.aspx. (accessed April 26, 2015)



- 15. Granulocyte. Medline Plus. http://www.nlm.nih.gov/medlineplus/ency/article/003440.htm. (accessed April 26, 2015).
- 16. What is an eosinophil? Cincinnati Center for Eosinophiic Disorders. http://www.cincinnatichildrens.org/service/c/eosinophilic-disorders/conditions/eosinophil/. (accessed April 26, 2015).
- 17. Basophils. PubMed Health. http://www.ncbi.nlm.nih.gov/pubmedhealth/PMHT0022054/. (accessed April 26, 2015).
- 18. Metcalfe DD, Baram D, Mekori YA. Mast cells. *Physiological Reviews*. 1997; 77(4): 1033-1079.
- 19. Immune cells and their products. National Institute of Allergy and Infectious Disease. http://www.niaid.nih.gov/topics/immunesystem/immunecells/pages/default.aspx. (accessed April 26, 2015).
- 20. Through the microscope: blood cells life's blood. Wadworth Center New York State Department of Health. http://www.wadsworth.org/chemheme/heme/microscope/monocyte.htm. (accessed April 26, 2015).
- 21. Microbiology: A Human Perspective, Eugene W. Nester. 6th edition. 2012 by the McGraw-Hill Companies, Inc.



- 22. Corthay A. How do regulatory T cells work? *Journal of Immunology*. 2009; 70:326-336.
- 23. Complement System. University of Washington. http://courses.washington.edu/conj/inflammation/complement.htm . (accessed April 26, 2015).
- 24. How to boost your immune system. Harvard Health Publications. http://www.health.harvard.edu/staying-healthy/how-to-boost-yourimmune-system. (accessed April 26, 2015).
- 25. Baron S, editor. Medical Microbiology. 4th edition. Galveston (TX): University of Texas Medical Branch at Galveston; 1996.
- 26. Lyme Disease. Centers for Disease Control and Prevention. http://www.cdc.gov/lyme/. (accessed April 28, 2015).
- 27. Lyme disease diagnosis. Lymedisease.org. http://www.lymedisease.org/lyme101/lyme_disease/lyme_diagno sis.html. (accessed April 28, 2015).



- 28. Patient information: Lyme disease symptoms and diagnosis (beyond the basics). UpToDate. http://www.uptodate.com/contents/lyme-disease-symptoms-and-diagnosis-beyond-the-basics. (accessed April 29, 2015).
- 29. Seere AC. Lyme disease. *N Engl J Med*. 1989;321(9):586.
- 30. Kalish RA, Kaplan RF, Taylor E, et al. Evaluation of study patients with Lyme disease, 10-20 year follow-up. *J Infect Dis*. 2001;183(3):453.
- 31. Peterson PK, Clawson CC, Lee DA, et al. Human phagocyte interactions with the Lyme disease spirochete. *Infect Immun*. 1984;46(2):608.
- 32. Xu Q, Seemanapalli SV, Reif KE, et al. Increasing the recruitment of neutrophils to the site of infection dramatically attenuates Borrelia burgdorferi infectivity. *J mmunol.* 2007;178(8):5109.
- 33. Hirschfeld M, Kirschning CJ, Schwander, et al. Cutting edge: inflammatory signaling by Borrelia burgdorferi lipoproteins in mediated by toll-like receptor 2. *J immunol*. 1999;163(5):2382.



- 34. Craft JE, Duncan KF, Shimamoto GT, et al. Antigens of Borrelia burgdorferi recognized during Lyme disease. *J Clin Invest.* 1986;78:934-939.
- 35. Steere AC, Schoen RT, Taylor E. The clinic evolution of Lyme arthritis. *Ann Intern Med*. 1987;107;725-731.
- 36. Auwaerter PG, Aucott J, Dumier JS. Lyme borreliosis (Lyme disease): molecular and cellular pathobiology and prospects for prevention, diagnosis and treatment. *Expert Rev Mol Med.* 2004;6(2):1-22.
- 37. Fibromyalgia. University of Maryland Medical Center. http://umm.edu/health/medical/reports/articles/fibromyalgia. (accessed April 29, 2015).
- 38. Fibromyalgia. The New York Times Health Guide. http://www.nytimes.com/health/guides/disease/fibromyalgia/conditions-with-similarsymptoms.html. (accessed April 29, 2015).
- 39. Infectious diseases. Mayo Clinic. http://www.mayoclinic.org/diseasesconditions/infectious-diseases/expert-answers/infectious-disease/FAQ-20058098?p=. (accessed April 29, 2015).
- 40. Chickenpox (varicella zoster infection). New York State Department of Health. https://www.health.ny.gov/diseases/communicable/chickenpox/fact_sheet.htm. (accessed April 29, 2015).



- 41. Diseases and conditions: shingles. Mayo Clinic. http://www.mayoclinic.org/diseasesconditions/shingles/basics/risk-factors/con-20019574. (accessed April 29, 2015).
- 42. Shingles (Herpes Zoster) Vaccination. Center for Disease Control and Prevention. http://www.cdc.gov/vaccines/vpd-vac/shingles/. (accessed April 29, 2015).
- 43. Seasonal Influenza (Flu). New York State Department of Health. https://www.health.ny.gov/diseases/communicable/influenza/seasonal/. (accessed April 29, 2015).
- 44. Influenza (flu). Centers for Disease Control and Prevention. http://www.cdc.gov/flu/. (accessed April 29, 2015).
- 45. Herpes simplex: signs and symptoms. American Academy of Dermatology. https://www.aad.org/dermatology-a-to-z/diseases-and-treatments/e---h/herpessimplex/signs-symptoms. (accessed April 29, 2015).
- 46. Herpes simplex: who gets and causes. American Academy of Dermatology. https://www.aad.org/dermatology-a-to-z/diseases-and-treatments/e---h/herpessimplex/who-gets-causes. (accessed April 29. 2015).
- 47. Herpes Simplex. MedlinePlus. http://www.nlm.nih.gov/medlineplus/herpessimplex.html#summary. (accessed April 29, 2015).



- 48. Infectious Mononucleosis (mono, EBV mononucleosis. New York State Department of Health. https://www.health.ny.gov/diseases/communicable/mononucleosis/fac t_sheet.htm. (accessed April 29, 2015).
- 49. Marth E, Jelovcan S, Kleinhappl B, et al. The effect of heavy metals on the immune system at low conentrations. *International Journal of Occupational Medicine and Environmental Health.* 2001;14(4):375-386.
- 50. Shrivastava R, Upreti Rk, Seth PK, et al. Effects of chromium on the immune system. *FEMS Immunology and Medical Microbiology*. 2002;34:1-7.
- 51. Theron AJ, Tintinger GR, Anderson R. Harmful interactions of nonessential heavy metals with cells of the innate immune system. *J Clin Toxicol.* 2012;S3:1-10.
- 52. Karalis K, Muglia LJ, Bae D, et al. CRH and the immune system. *Journal of Neuroimmunology*. 1997;72:131-136.
- 53. Torpy DJ, Chrousos GP. The three-way interactions between the hypothalamic-pituitary-adrenal and gonadal axes and the immune system. *Balliere's Clinical Rheumatology.* 1996;10(2): 181-198.



- 54. Lin TM, Lustig RH, Chang C. The role of androgens-androgen receptor in immune system activity. In: The Physiology of Immunity. CRC Press, Inc. 1996:263-276.
- 55. Flier JS, Underhill LH. The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. *Seminars in the Medicine of the Beth Israel Hospital, Boston.* 1995;332(20):1351-1362.
- 56. Silverman MN, Pearce BD, Biron CA, et al. Immune modulation of the hypothalamic-pituitary-adrenal (HPA) axis during viral infection. *Viral Immunol.* 2005;18(1):41-78.
- 57. Chen CCG, Park CR. Adrenal androgens and the immune system. Seminars in Reproductive Medicine. 2004;22(4):368-377.
- 58. Lahita RG. The role of sex hormones in system lupus erythematosus. *Curr Opin Rheumatol*. 1999; 11: 352-356.
- 59. Pervasive Developmental Disorders. WebMd. http://www.webmd.com/brain/autism/development-disorder. (accessed May 10, 2015).



- 60. Heavy metals and autism, PDD, and ADHD. TreatAutism&ADHD. http://treatautism.ca/detoxification/heavy-metals/. (accessed May 10, 2015).
- 61. Heavy metal suppression of the immune system. *Journal of Advancement in Medicine*. 1989: 2(1):1.
- 62. Forrest BD. Environmental contaminants and the immune system. *Blacksmith Institute.*
- 63. Heavy Metal Detoxification. LifeExtension. http://www.lifeextension.com/Protocols/Health-Concerns/Heavy-Metal-Detoxification/Page-07. (accessed May 15, 2015).
- 64. Hormone balance hormone imbalance: how it affects the immune system. Immune System: Hormone Balance & Imbalance. http://immunedisorders.homestead.com/hormones.html. (accessed May 16, 2015).
- 65. Bhalla AK. Hormones and the immune response. Annals of Rheumatic Diseases. 1989;48:1-6.



- 66. Bernton E, Hoover D, Galloway R, et al. Adaption to chronic stress in military trainees. *Annals New York Academy of Sciences*. 1995;774(1):217-231.
- 67. D'Agostino P, Milano S, Barbera C, et al. Sex hormones modulate inflammatory mediators produced by macrophages. *Annals New York Academy of Sciences*. 1999;87(1):426-429.
- 68. Yen SSC, Morales AJ, Khorram O. Replacement of DHEA in aging men and women. *Annals News York Academy of Sciences.* 1995;774(1):128-142.
- 69. Bikle D. Vitamin D: an ancient hormone. *Experimental Dermatology*. 2010;20:7-13.
- 70. Bennington V. How sleep deprivation fries your hormones, your immune system, and your brain. Breaking Muscle. http://breakingmuscle.com/health-medicine/how-sleep-deprivation-fries-your-hormones-your-immune-system-and-your-brain. (accessed May 16, 2015).
- 71. Klein JR. The immune system as a regulator of thyroid hormone activity. *Exp Biol Med (Maywood)*. 2006;23(3):229-236.
- 72. Reichlin S. Neuroendocrine-immune interactions. *New Eng J Med.* 1993;329(17):1246-1253.




<u>sswidan@umich.edu</u> 734-821-8000

